scispace - formally typeset
A

Aleš Linhart

Researcher at First Faculty of Medicine, Charles University in Prague

Publications -  371
Citations -  36568

Aleš Linhart is an academic researcher from First Faculty of Medicine, Charles University in Prague. The author has contributed to research in topics: Fabry disease & Medicine. The author has an hindex of 50, co-authored 333 publications receiving 30467 citations. Previous affiliations of Aleš Linhart include University Hospital of Wales & Charles University in Prague.

Papers
More filters
Journal ArticleDOI

Normative reference ranges for echocardiographic chamber dimensions in a healthy Central European population: results from the Czech post-MONICA survey

TL;DR: In this article, the authors provided reference ranges for echocardiographic measurements obtained in a healthy subgroup derived from an epidemiological study of a Central European population, where the whole population sample with predefined percentile cutoffs was used to define degrees of abnormality.
Journal ArticleDOI

Takotsubo cardiomyopathy in a patient with essential thrombocythemia treated with anagrelide: Case report

TL;DR: Nase kasuisticke sděleni jako prvni v Ceske republice popisuje p�’ipad tako-tsubo kardiomyopatie vznikle v souvislosti s podavanim vysokých davek anagrelidu.
Journal ArticleDOI

Longitudinal trends in blood pressure, prevalence, awareness, treatment, and control of hypertension in the Czech population. Are there any sex differences?

TL;DR: In this article , the authors assess longitudinal trends in blood pressure, prevalence, awareness, treatment, and control of hypertension in a representative population sample of the Czechia from 1985 to 2016/2017, focusing on sex differences.
Journal ArticleDOI

Nationwide screening of Fabry disease in patients with hypertrophic cardiomyopathy in Czech Republic

TL;DR: The findings advocate a routine screening for FD in all adult patients with HCM phenotype including both genders, and confirm the prevalence of FD repeatedly reported in previous screening programmes in a non-selected HCM population in Central Europe.